Atlas Trials

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

Clinical trial NCT07205822 · RECRUITING

Trial details

NCT number
NCT07205822
Sponsor
AstraZeneca
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2025-10-30
Primary completion
2028-02-02
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.